Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

After a slight delay, the FDA rejected Stealth BioTherapeutics' Barth syndrome drug application for elamipretide, but will ...

The CDC will no longer recommend routine Covid-19 vaccines for healthy kids and pregnant women after HHS Secretary Robert F.

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

As of Thursday morning, just over 300 entries out of at least 950 public comments have been released by the Department of ...

The US Supreme Court will continue deciding whether to take up a pivotal case on state PBM regulation after the federal ...

Novo Nordisk warned the US government not to impose pharma-specific tariffs, but instead to tax illegal importers of ...

Prothena abandons birtamimab after Phase 3 amyloidosis trial failure, plans layoffs. Drug previously failed mid-stage trial.

The companies said Thursday that they voluntarily withdrew the accelerated approval request for patritumab deruxtecan in ...

Protein degrader shop GlycoEra, spun out of vaccines company LimmaTech in 2021, has corralled $130 million in Series B ...

Strand Therapeutics reports early positive data for STX-001, a self-replicating mRNA cancer therapy, showing safety and ...